CompletedNot Applicable

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)

Thailand300 participantsStarted 2017-10-18

Plain-language summary

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) to gain insight into the safety (bleeding, liver adverse events, all-cause mortality and other adverse events) of edoxaban use in non-preselected patients with NVAF.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Is a NVAF-patient whose physician has made the clinical decision to prescribe edoxaban therapy according to Package Information * Has provided written informed consent to participate in the study Exclusion Criteria: * Is participating in an interventional study

What they're measuring

Number of participants with real world safety events

Timeframe: 2 years

Trial details

NCT IDNCT03247569

SponsorDaiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-02-28

View on ClinicalTrials.gov More Atrial Fibrillation trials